125 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVS Novartis AG $85.13 $197.65B Downtrend
Article Searches
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4243438-galapagos-nv-glpg-ceo-onno-van-de-stolpe-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 22, 2019 - Galapagos NV (NASDAQ:GLPG) Q4 2018 Earnings Conference Call February 22, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - Chief Executive Officer Bart
PostNL NV (PNLYY) CEO Hendrika Verhagen on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4244047-postnl-nv-pnlyy-ceo-hendrika-verhagen-q4-2018-results-earnings-call-transcript?source=feed_sector_transcripts Feb 25, 2019 - PostNL NV (OTCPK:PNLYY) Q4 2018 Earnings Conference Call February 25, 2019, 05:00 ET Company Participants Hendrika Verhagen - Chairman & CEO Jochem van de Laarschot - Director Communications &
Orthofix International NV (OFIX) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/25/orthofix-international-nv-ofix-q4-2018-earnings-co.aspx?source=iedfolrf0000001 Feb 25, 2019 - OFIX earnings call for the period ending December 31, 2018.
Anheuser-Busch InBev SA/NV (BUD) CEO Carlos Brito on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4245387-anheuser-busch-inbev-sa-nv-bud-ceo-carlos-brito-q4-2018-results-earnings-call-transcript?source=feed_sector_transcripts Feb 28, 2019 - Anheuser-Busch InBev SA/NV (NYSE:BUD) Q4 2018 Earnings Conference Call February 28, 2019 9:00 a.m. ET Company Participants Carlos Brito - CEO Felipe Dutra - Chief Financial and Solutions Officer Confe
Playa Hotels & Resorts NV (PLYA) CEO Bruce Wardinski on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4245802-playa-hotels-and-resorts-nv-plya-ceo-bruce-wardinski-q4-2018-results-earnings-call-transcript?source=feed_sector_transcripts Mar 01, 2019 - Playa Hotels & Resorts NV (NASDAQ:PLYA) Q4 2018 Earnings Conference Call March 01, 2019 9:00 AM ET Company Participants Ryan Hymel - Executive Vice President & Chief Financial Officer Bruce Wa
Ligand Sells Promacta Rights for $827M, Updates '19 View http://www.zacks.com/stock/news/357855/ligand-sells-promacta-rights-for-%24827m-updates-19-view?cid=CS-ZC-FT-357855 Mar 06, 2019 - Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy http://www.zacks.com/stock/news/358436/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358436 Mar 08, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer http://www.zacks.com/stock/news/358936/roches-rhhby-tecentriq-gets-fda-approval-for-breast-cancer?cid=CS-ZC-FT-358936 Mar 12, 2019 - Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Roche Receives EC Approval for Label Expansion of Hemlibra http://www.zacks.com/stock/news/359564/roche-receives-ec-approval-for-label-expansion-of-hemlibra?cid=CS-ZC-FT-359564 Mar 14, 2019 - Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys? https://www.fool.com/investing/2019/03/19/3-blue-chip-stocks-that-just-hit-52-week-highs-are.aspx?source=iedfolrf0000001 Mar 19, 2019 - Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

Pages: 123456...13

Page 1>